Biogen Inc

詳細情報 Biogen Inc 企業名

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

企業情報

企業コードBIIB

会社名Biogen Inc

上場日Sep 17, 1991

最高経営責任者「CEO」Mr. Christopher A. (Chris) Viehbacher

従業員数7605

証券種類Ordinary Share

決算期末Sep 17

本社所在地225 Binney Street

都市CAMBRIDGE

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号02142

電話番号17814642000

ウェブサイトhttps://www.biogen.com/

企業コードBIIB

上場日Sep 17, 1991

最高経営責任者「CEO」Mr. Christopher A. (Chris) Viehbacher

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

Mr. Jesus B. Mantas

Independent Director

8.42K

+39.19%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

5.77K

-8.22%

Dr. Maria C. Freire, Ph.D.

Independent Director

5.47K

+76.33%

Ms. Susan Langer

Independent Director

3.79K

+166.90%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Spinal Muscular Atrophy-SPINRAZA

563.30M

23.17%

MS product revenues-TYSABRI

381.50M

15.69%

MS product revenues-Fumarate

344.90M

14.19%

MS product revenues-Interferon

226.30M

9.31%

Biosimilar product revenues-BENEPALI

111.30M

4.58%

他の

803.70M

33.06%

地域別USD

会社名

収益

比率

Rest of World

972.70M

40.01%

United States

786.80M

32.37%

United states-Revenues from anti-CD20 therapeutic

378.20M

15.56%

Rest of World-Other revenues

293.30M

12.06%

事業別

地域別

事業別USD

会社名

収益

比率

Spinal Muscular Atrophy-SPINRAZA

563.30M

23.17%

MS product revenues-TYSABRI

381.50M

15.69%

MS product revenues-Fumarate

344.90M

14.19%

MS product revenues-Interferon

226.30M

9.31%

Biosimilar product revenues-BENEPALI

111.30M

4.58%

他の

803.70M

33.06%

株主

更新時刻: Tue, Aug 19

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

11.74%

PRIMECAP Management Company

10.78%

BlackRock Institutional Trust Company, N.A.

5.59%

State Street Global Advisors (US)

5.09%

Wellington Management Company, LLP

3.27%

他の

63.53%

株主統計

比率

The Vanguard Group, Inc.

11.74%

PRIMECAP Management Company

10.78%

BlackRock Institutional Trust Company, N.A.

5.59%

State Street Global Advisors (US)

5.09%

Wellington Management Company, LLP

3.27%

他の

63.53%

種類

株主統計

比率

Investment Advisor

51.54%

Investment Advisor/Hedge Fund

24.22%

Hedge Fund

8.68%

Pension Fund

2.62%

Research Firm

2.27%

Sovereign Wealth Fund

1.60%

Bank and Trust

1.38%

Individual Investor

0.17%

Venture Capital

0.14%

他の

7.38%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

2075

135.74M

92.58%

-12.69M

2025Q1

2149

136.82M

93.38%

-11.44M

2024Q4

2130

138.58M

94.69%

-5.19M

2024Q3

2109

135.95M

93.33%

-6.54M

2024Q2

2116

135.72M

93.21%

-7.14M

2024Q1

2121

136.44M

93.87%

-5.95M

2023Q4

2151

135.61M

93.59%

-2.07M

2023Q3

2177

132.42M

91.43%

-7.53M

2023Q2

2240

133.77M

92.42%

-4.86M

2023Q1

2280

132.71M

91.84%

-5.88M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

16.96M

11.57%

+279.20K

+1.67%

Mar 31, 2025

PRIMECAP Management Company

15.94M

10.88%

-102.95K

-0.64%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

8.70M

5.94%

+106.24K

+1.24%

Mar 31, 2025

State Street Global Advisors (US)

7.40M

5.05%

-1.34K

-0.02%

Mar 31, 2025

Wellington Management Company, LLP

4.67M

3.19%

-258.29K

-5.24%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.85M

2.63%

+151.39K

+4.10%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

3.03M

2.07%

-8.46K

-0.28%

Jun 30, 2025

Norges Bank Investment Management (NBIM)

2.33M

1.59%

+246.45K

+11.86%

Dec 31, 2024

Invesco Capital Management LLC

2.01M

1.37%

+124.81K

+6.62%

Mar 31, 2025

詳細を見る

142.500USD

Biogen Inc

142.500

概要

企業名

金融

分析